logo

Nightstar Therapeutics Plc (NITE)



Trade NITE now with
  Date
  Headline
11/13/2018 1:29:06 AM Nightstar Therapeutics Expects Preliminary Efficacy Data From Phase 2/3 Expansion Study In Mid-2019
9/27/2018 9:20:03 PM Nightstar Therapeutics Prices Public Offering Of 4 Mln ADSs At $18.00/ADS
9/25/2018 7:50:52 AM Wedbush Is Lowering Nightstar Therapeutics plc (NITE) FY18 Estimate To -1.61 From -1.59
9/25/2018 7:50:34 AM Wedbush Is Cutting Nightstar Therapeutics plc (NITE) Q3 18 Estimate To -0.43 From -0.42
9/25/2018 7:49:56 AM Wedbush Reiterates Nightstar Therapeutics plc (NITE) At Outperform With $36 Up From $31 Price Target
9/22/2018 12:01:57 PM Nightstar Says Positive Proof Of Concept Data From Dose Escalation Study In XIRIUS Trial For NSR-RPGR In XLRP Patients
8/13/2018 6:10:05 AM Nightstar Therapeutics Q2 Net Loss $8.1 Mln Or $0.29/Shr Vs Loss $4.2 Mln Or $0.18/shr Last Year
7/25/2018 10:04:59 AM Wedbush Reiterates Nightstar Therapeutics plc (NITE) At Outperform With $31 Price Target
6/14/2018 6:11:06 AM Nightstar Therapeutics Gets Regenerative Medicine Advanced Therapy Designation For NSR-REP1 In Choroideremia
6/6/2018 3:53:34 PM Wedbush Is Lowering Nightstar Therapeutics plc (NITE) FY18 Estimate To -2.13 From -1.17
6/6/2018 3:53:15 PM Wedbush Is Lowering Nightstar Therapeutics plc (NITE) Q4 18 Estimate To -0.50 From -0.28
6/6/2018 3:52:58 PM Wedbush Is Lowering Nightstar Therapeutics plc (NITE) Q3 18 Estimate To -0.57 From -0.31
6/6/2018 3:52:38 PM Wedbush Is Lowering Nightstar Therapeutics plc (NITE) Q2 18 Estimate To -0.55 From -0.29
6/6/2018 3:51:56 PM Wedbush Reiterates Nightstar Therapeutics plc (NITE) At Outperform With $31 Price Target
6/6/2018 6:37:28 AM Nightstar Therapeutics Q1 Net Loss $14.4 Mln Or $0.52/Shr Vs Loss $3.5 Mln Or $0.30/Shr Last Year